News

Iclepertin shows no significant cognitive improvement in schizophrenia patients despite good tolerability, highlighting challenges in treating cognitive impairment.

EXCLUSIVE: Check out this recap on the approval of lumateperone (Caplyta) for major depressive disorder.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

"Without a father to guide me north, your poems were a compass pointing toward a world where doctors can be poets..."

FDA committee discusses potential and risks of AI-enabled digital mental health devices.

A recent study links lower income to higher dementia risk factors, highlighting the need for targeted interventions in vulnerable populations.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.

Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.

Explore the evolving understanding of haloperidol's risks and the shift towards safer alternatives in delirium management and psychiatric care.

Veterans face significant PTSD challenges, with tailored treatments and ongoing research essential for improving their mental health outcomes.

Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.

Dive into poetic reflections on life and aging.

Explore the profound reflections of AI on human experiences, emotions, and the potential impact of chatbots in therapy and daily life.

Women veterans face unique challenges and mental health disparities, highlighting the urgent need for gender-sensitive care and support systems.

New research reveals hyperbaric oxygen therapy as a promising treatment for chronic PTSD, enhancing brain function and providing lasting symptom relief.

This Veterans Day, explore the lasting impact of trauma on veterans and the importance of addressing PTSD in our communities.

Psyence BioMed phase 2b trial explores psilocybin therapy for adjustment disorder in palliative care, aiming for groundbreaking treatment advancements.

Submit articles, 1000 to 1800 words in length, on use of the PRiSM instrument in research or clinical practice by January 31, 2026.

Eleanor Roosevelt's legacy inspires today's leaders to champion human rights, emphasizing mental health and the ongoing fight against discrimination.

AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.

FDA approves Caplyta for major depressive disorder, a new sNDA for Alzheimer disease, and news in correctional psychiatry.

Mentalization-based treatment offers innovative strategies to effectively address the challenges of narcissistic personality disorder and enhance emotional understanding.

Explore the profound connections between Thornton Wilder's "Our Town," psychiatry, and the importance of appreciating life's everyday moments.

Explore the intertwined stories of Lucy Grealy and Anne Patchett, revealing deep insights into mental health, beauty, and friendship.

Explore the vital connection between spirituality and mental health.

Explore the innovative PRiSM diagnostic tool, bridging categorical and dimensional approaches to enhance psychiatric diagnosis and treatment. Then submit your experiences for the chance to win publication and $500.

These are the legal, Official Rules for our Psychiatric Times PRiSM Contest.